30th October 2020
07:00

AIM - Cancellation - Verona Pharma PLC

29th October 2020
07:00

Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2020

28th October 2020
11:01

Verona Pharma plc : Update on AIM Delisting

23rd October 2020
16:30

FTSE Russell - Verona Pharma

22nd October 2020
06:00

Verona Pharma to Announce Interim Results for the Three and Nine Months Ended September 30, 2020 and Provide Corporate Update

13th October 2020
09:44

13th October 2020
06:00

Verona Pharma to Present Phase 2b COPD Symptom and Quality of Life Data with Ensifentrine at CHEST 2020

23rd September 2020
08:06

Verona Pharma Initiates Phase 3 Clinical Trials with Nebulized Ensifentrine for the Maintenance Treatment of COPD

21st September 2020
11:36

21st September 2020
06:00

Intended Delisting and Cancellation of Ordinary Shares from Trading on AIM

17th September 2020
10:48

17th September 2020
06:00

Verona Pharma to Ring the Nasdaq Closing Bell to celebrate $200 million financing

16th September 2020
12:25

Verona Pharma Announces Publication of Phase 2b COPD Symptom Data in the International Journal of Chronic Obstructive Pulmonary Disease

8th September 2020
06:00

Verona Pharma Initiates Pilot Study with pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19

2nd September 2020
06:00

Verona Pharma to Present at H.C. Wainwright 22nd Annual Global Virtual Investment Conference

26th August 2020
09:19

Verona Pharma plc: Grant of RADSUs and PDMR Dealings

24th August 2020
06:00

Verona Pharma to Present Phase 2b data with Ensifentrine in COPD at the European Respiratory Society International Congress 2020

19th August 2020
06:00

Verona Pharma Initiates Multiple Dose Part of Phase 2 Clinical Trial with pMDI Formulation of Ensifentrine in COPD

Verona Pharma Plc (VRP.L) Share Price & News

Bid

-

-

-

Ask

High
-
OPEN
-
VOL
-
MKT CAP
-M

LOW
-
CLOSE
-
SHARES IN ISSUE
414.55M

Verona Pharma Plc RNS

Watchlist